title: Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B.
abstract: OBJECTIVE
  To investigate the in vitro effect of entecavir (ETV) on the function of dendritic cells (DCs) derived from chronic hepatitis B (CHB) patients.
  
  
  METHODS
  Mononuclear cells were isolated from peripheral blood of patients with CHB. DCs were incubated with RPMI-1640 medium supplemented with fetal bovine serum, IL-4, granulocyte-macrophage colony-stimulating factor (GM-CSF). DCs were treated with or without ETV on the fourth day. Cell surface molecules, including CD1a, CD80, CD83 and HLA-DR, were assessed by flow cytometry. Concentrations of IL-6 and IL-12 in the supernatant were assayed by enzyme-linked immunosorbent assay (ELISA). The ability of the generated DCs to stimulate lymphocyte proliferation was observed.
  
  
  RESULTS
  Compared with CHB control group, the expression levels of CD1a (29.07 +/- 3.20 vs 26.85 +/- 2.80), CD83 (25.66 +/- 3.19 vs 23.21 +/- 3.10), CD80 (28.00 +/- 2.76 vs 25.75 +/- 2.51) and HLA-DR (41.96 +/- 3.81 vs 32.20 +/- 3.04) in ETV-treated group were higher (P < 0.05). ETV-treated group secreted significantly more IL-12 (157.60 +/- 26.85 pg/mL vs 132.60 +/- 22.00 pg/mL (P < 0.05) and had a lower level of IL-6 in the culture supernatant (83.05 +/- 13.88 pg/mL vs 93.60 +/- 13.61 pg/mL, P < 0.05) than CHB control group. The ability of DCs to stimulate the proliferation of allogeneic lymphocytes was increased in ETV-treated group compared with CHB control group (1.53 +/- 0.09 vs 1.42 +/- 0.08, P < 0.05).
  
  
  CONCLUSIONS
  Entecavir can enhance the biological activity of DCs derived from CHB patients.
authors.affiliation: Department of Gastroenterology, The Second Affiliated Hospital of Zhengzhou University, 2 Jingba Rd, Zhengzhou 450014, Henan Province, China.
authors.forename: Gao-Feng
authors.initials: GF
authors.lastname: Lu
authors.forename: Fu-Ai
authors.initials: FA
authors.lastname: Tang
authors.forename: Peng-Yuan
authors.initials: PY
authors.lastname: Zheng
authors.forename: Ping-Chang
authors.initials: PC
authors.lastname: Yang
authors.forename: Yuan-Ming
authors.initials: YM
authors.lastname: Qi
mesh_terms: D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D018949:Antigens, CD1 / Q000378:metabolism; D000998:Antiviral Agents / Q000494:pharmacology*; D018122:B7-1 Antigen / Q000378:metabolism; D016022:Case-Control Studies; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006684:HLA-DR Antigens / Q000378:metabolism; D019694:Hepatitis B, Chronic / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008214:Lymphocytes / Q000187:drug effects; D008562:Membrane Glycoproteins / Q000378:metabolism; D010641:Phenotype; D000097802:CD83 Antigen
chemical_list: D015703:Antigens, CD; D018949:Antigens, CD1; D000998:Antiviral Agents; D018122:B7-1 Antigen; D006147:Guanine; D006684:HLA-DR Antigens; D007136:Immunoglobulins; D018664:Interleukin-12; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D000097802:CD83 Antigen; C419393:CD1a antigen; C413685:entecavir